Taiwan Bio Completes TregCel Transfer, Phase 2 Trial on Horizon

• Taiwan Bio Therapeutics and TRACT Therapeutics successfully transferred TregCel platform technology to Taiwan Bio’s GMP facility.

• The companies are preparing for a global Phase 2 trial in kidney transplant patients, set to commence in Taiwan and the U.S.

Taiwan Bio Therapeutics, Inc. and TRACT Therapeutics, Inc. have achieved a key milestone with the successful transfer of TRACT’s TregCel platform technology to Taiwan Bio’s GMP cell manufacturing facility.

The partnership, established in December 2023, combines Taiwan Bio’s expertise in cellular therapy manufacturing with TRACT Therapeutics’ regulatory T cell therapy platform, TregCel. The upcoming Phase 2 trial, set to begin simultaneously in Taiwan and the United States, follows a Phase 1 study that demonstrated both safety and potential efficacy of the Treg product. The trial could potentially shift the treatment paradigm by reducing transplant patients’ dependence on immunosuppressant drugs.

Cyrus Yang, CEO of Taiwan Bio Therapeutics, expressed optimism about the transfer, noting, “This achievement underscores our commitment to advancing cutting-edge cellular therapies. We look forward to supporting the upcoming trial and the global manufacturing needs of this innovative therapy.”

Dr. Joseph Leventhal, Scientific Founder of TRACT Therapeutics, emphasized the importance of the collaboration, stating, “The successful technology transfer is a crucial step in our journey to bring this therapy to patients. The partnership with Taiwan Bio aligns perfectly with our mission to develop transformative therapies.”